Biotech Startup Funding Has Also Slowed In 2022

Biotech Startup Funding Has Also Slowed In 2022
After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last year’s levels.

The slowdown comes amid a broader pullback in global venture funding. Across all sectors, investment hit its zenith in November and has been cresting downward since. On the exit front, meanwhile, the pace of venture-backed IPOs has slowed to a crawl.

Biotech funding follows the general pattern. In the U.S., biotech startups have raised a total of $16.5 billion so far this year, or about $3.2 billion on average per month. In all of 2021, however, nearly $47 billion went into the space, an average of nearly $4 billion per month.